Tumor markers in prostate cancer I: Blood-based markers Review uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Prostatic Neoplasms

abstract

  • PSA is a strong prognostic marker for long-term risk of clinically relevant cancer. However, there is a need for novel biomarkers that aid clinical decision making about biopsy and initial treatment. There is no doubt that progress will continue based on the integrated collaboration of researchers, clinicians and biomedical firms.

publication date

  • June 2011

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3571678

Digital Object Identifier (DOI)

  • 10.3109/0284186X.2010.542174

PubMed ID

  • 21604943

Additional Document Info

start page

  • 61

end page

  • 75

volume

  • 50

number

  • SUPPL. 1